Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons
Nischal Ranganath, John C. O’Horo, Douglas W. Challener, Sidna M. Tulledge‐Scheitel, Marsha L. Pike, M D O’Brien, Raymund R. Razonable, Aditya Shah
Abstract
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.
Topics & Concepts
MedicineRitonavirCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakInternal medicineCoronavirusCohortCohort studyRetrospective cohort studyVirologyDiseaseViral loadVirusAntiretroviral therapyInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchInfectious Encephalopathies and Encephalitis